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Despite major advances in therapy, survival of patients with breast
cancer has not substantially improved. The search for reliable and
sensitive prognostic tests is critical as they may help to identify
patients for whom intensive adjuvant therapy is worthwhile.
Histology alone is subjective and often not predictive of clinical
behaviour. Many different tumour characteristics and cell compo-
nents have been evaluated for prognostic significance in breast
cancer. Regulatory and structural alterations of oncogenes appear
to be one of the key events in the formation of most human
cancers. Proto-oncogenes are present in all mammalian cells and
are involved in normal growth and differentiation. Deregulated
activation of the same genes can contribute to cancer development
(Alitalo and Schwab, 1986). In particular, the presence of ampli-
fied oncogenes has been widely reported in human tumours, and in
many cases a correlation of amplification degree with clinical
indicators was detected.
Expression of the c-myc proto-oncogene is involved in the regu-
lation of cellular proliferation and terminal differentiation of
human cells. Amplification of c-myc seems to associate with poor
prognosis in breast cancer (Varley et al, 1987; Berns et al, 1992,
1996; Borg et al, 1992; Rous-Dosseto et al, 1992; Kreipe et al,
1993; Pertschuk et al, 1993; Pietilainen et al, 1995; Nass and
Dickson, 1997) and to be a prognostic marker in node-negative
patients (Berns et al, 1992; Borg et al, 1992). The c-myc oncogene
produces a nuclear DNA-binding protein whose expression is
regulated by oestrogen and down-regulated by tamoxifen in
hormone-responsive human breast cancer in vitro (Santos et al,
1988; Van der Burg et al, 1989). Oestrogens are potent mitogens in
a number of target tissues, including mammary glands where they
play a pivotal role in the development and progression to
mammary carcinoma. Oestrogens regulate the expression and
function of c-myc and cyclin D1 and activate cyclin E–CdK2
complexes, all of which are rate-limiting for progression from G1
to S phase (Prall et al, 1998).
Reverse effects have been shown with respect to c-erbB-2
expression (Dati et al, 1990; Read et al, 1990), i.e. oestrogen
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Summary C-myc and c-erbB-2 amplification and/or overexpression as well as total cathepsin-D (CD) concentration have been reported to be
associated with poor prognosis in breast cancer. The prognostic significance, however, remains somewhat controversial, partly because of
discrepancies among the different methodologies used. We determined the amplification and overexpression of c-myc oncogene in 152
breast cancer patients and examined its prognostic value in relation to c-erbB-2 amplification and overexpression, high concentration of CD
(³ 60 pmol mg–1 protein) and standard clinicopathological prognostic factors of the disease. High CD concentration, as well as c-myc
amplification and overexpression, proved to be the best of the new variables examined for prediction of early relapse (ER; before 3 years).
After multivariate analysis only CD remained significant, which suggests that the prognostic power of these variables is similar. Using
univariate analysis we proved that c-myc amplification and overexpression were highly significant for disease-free survival (DFS) (P = 0.0016
and P = 0.0001 respectively) and overall survival (OS) (P < 0.0001 and P = 0.0095 respectively), although by multivariate analysis c-myc
overexpression was statistically significant only for DFS (P = 0.0001) and c-myc amplification only for OS (P = 0.0006). With regard to
c-erbB-2, only its overexpression appeared to be significant for DFS and OS, although after multivariate analysis its prognostic power was
weaker (P = 0.030 and P = 0.024 respectively). c-myc amplification and overexpression exhibited a tendency for locoregional recurrence
(LRR) (P = 0.0024 and P = 0.0075 respectively), however, their prognostic value was lower after multivariate analysis and only CD remained
significant. © 1999 Cancer Research Campaign
Keywords: c-myc; c-erbB-2; cathepsin-D; early relapse; relapse-free survival; overall survival; locoregional recurrence; breast cancer
1385
British Journal of Cancer (1999) 81(8), 1385–1391
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0856
Received 15 December 1998
Revised 12 April 1999
Accepted 25 May 1999
Correspondence to: M Talieri, Papanikolaou Research Centre of Oncology –
Saint Savas Hospital, 171 Alexandras Avenue, Athens 11522, Greece
*Present address: Department of Pathology and Laboratory Medicine, Mount Sinai
Hospital and Department of Laboratory Medicine and Pathobiology, University of
Toronto, 600 University Avenue, Toronto, Ontario M5G 1X5 Canadadown-regulated the expression of c-erbB-2 and this effect was
reversed by anti-oestrogens. It has been hypothesized that the
activation of the two genes might share the same metabolic
pathway; in fact, the c-erbB-2 gene has been identified as a
cellular target for negative regulation by c-myc (Suen and Hung,
1991), whereas c-erbB-2 tyrosine kinase-mediated signals seem to
down-regulate the immediate-early genes (Sistonen et al, 1990).
To express its full potential in systemic disease, however, the
gene may have to act in concert with other events which also
render the cell capable of metastasizing. Tumours with activated
c-erbB-2 show several characteristics of the aggressive phenotype
and are implicated in early relapse and shortened overall survival
(Allred et al, 1998; Sjogren et al, 1998). One of the molecular
mechanisms involved in the process of metastasis may be over-
production of proteases that degrade the basement membrane and
the extracellular matrix (Rochefort, 1992). The most extensively
studied protease in human breast cancer is cathepsin-D (CD).
Several reports on the prognostic value of CD in breast cancer
have revealed poor survival for patients with high CD levels
(Spyratos et al, 1989; Scorilas et al, 1993, 1995, 1999; Ferradina
et al, 1997; Losch et al, 1998).
The present analysis was designed to extend and complete our
previous work (Scorilas et al, 1993, 1995, 1999) and to assess the
prognostic significance of the overexpression and amplification of
c-myc in relation to various established prognostic factors as well
as c-erbB-2 oncogene amplification and overexpression and CD
concentration in Greek breast cancer patients, in an effort to better
characterize this marker. The interrelationship was tested by
univariate and multivariate analysis in a series of 152 breast cancer
patients with a median follow-up of 5 years in our hospital.
MATERIALS AND METHODS
Patients
Tumour specimens from 152 patients (age: mean, 60 years; range
24–92 years) with no signs of distant metastasis and who
underwent surgery for primary breast cancer from 1990 to 1995
(modified mastectomy 50 patients (32.9%); breast-conserving
lumpectomy 102 patients (67.1%)) at the Oncologic Hospital of
Athens ‘St Savas’, were evaluated in this study. Tumour speci-
mens were drawn from a pool of frozen specimens originally
submitted to the Laboratory of Hormone Receptors for steroid
receptor analysis. Most of the women with positive lymph
nodes generally received adjuvant chemotherapy (cyclophos-
phamide–methotrexate–5-fluorouracil for 6 cycles every 28 days;
70 patients); 102 patients received adjuvant (Tamoxifen) therapy
(20 mg daily for 5 years), whereas 115 were irradiated. Twenty-
one patients (13.8%) developed locoregional recurrence. Median
follow-up for patients was 5 years (range 4–8 years). A computer-
ized database containing updated information concerning each
patient, together with receptor status, nodal status, size of the
primary tumour, number of positive nodes, age and menopausal
status of the patients, and/or differentiation grade of the tumour,
was available for statistical analysis.
Tumour sample processing
Tumour tissue was stored in liquid nitrogen. Samples were
processed as we described previously (Scorilas et al, 1993, 1995).
Tissue was pulverized in the frozen state and homogenized in 5 ml
cytosol buffer (10 mM Tris, 1.5 mM EDTA, 5 mM NaMolybdate
pH = 7.4, 5 mM dithiothreiol DTT). The homogenates were
subjected to centrifugation at 40 000 rpm for 1 h at 4°C and the
cytosols were kept at –80°C for later processing. The same
cytosols were used for hormone receptors and for CD assays.
DNA was isolated from 100 mg of tumour tissue, which was
minced finely using a pair of scalpels, dispersed in 1 ml of
2 ´ TNE (20 mM Tris pH = 8.0, 300 mM NaCI, 20 mM EDTA)
containing 0.5% sodium dodecyl sulphate (SDS) and digested
with proteinase K (100 mg ml–1) at 37°C. After repeated phenol,
phenol–chloroform and chloroform–isoamyl alcohol extractions,
intact genomic DNA was pooled following precipitation with 2
volumes of ethanol. RNA was isolated from frozen samples,
ground to a fine powder in liquid nitrogen and subsequently
homogenized in an acid guanidine thiocyanate–phenol–chloro-
form solution according to Chomczynski et al (1987). Southern
blotting of EcoR1-digested DNA was performed by standard
techniques (Feinberg and Vogelstein, 1983; Thomas, 1980). The
integrity of the RNA was confirmed by formaldehyde-agarose gel
electrophoresis. Northern blotting was performed according to
Thomas (1980). Equal amounts of DNA (20 mg) were slot blotted
on nylon membranes (Hybond N+, Amersham). RNA (20 mg) was
slot blotted according to Maniatis et al (1982).
Detection of oncogenes
To determine c-myc overexpression or amplification, blots were
hybridized overnight at 42°C to randomly primed [a-32P]dCTP-
labelled c-myc probe (1.3 kb fragment, ClaI-EcoRI, from pHSR-1
plasmid-PBR 322-HindIII EcoRI-human genomic c-myc exon 3
from Colo 320-ATCC). To determine c-erbB-2 overexpression or
amplification, blots were hybridized to c-erbB-2 (Oncogene
Science) by a 5¢ end labelling procedure (Promega), using
[g32P]ATP. The hybridization was performed according to the
instructions of the manufacturer and others (Miyada and Wallace,
1987). Briefly, after washing the blots at high stringency (2 ´ CCS,
0.1% SDS), autoradiography with intensifying screens was
performed for 2–4 days at –70°C using Kodak X-OMAT-100 films
and autoradiograms were scanned with a BioRad video densito-
meter 620. DNA and RNA extracted from paired normal breast
tissue (obtained from radical mastectomies from areas distant to
the cancer) was used as normal control. The values obtained for
c-myc and c-erbB-2 by densitometer scanning were normalized to
values obtained for b-actin. The ratios obtained were compared
to average values obtained from 25 normal samples processed in
order to determine amplification or overexpression.
Hormone receptors
Oestrogen and progesterone receptors were assayed by ligand
binding assay procedure using the dextran-coated charcoal tech-
nique as previously described (EORTC Breast Cancer Group,
1980; Kute et al, 1980). Results were expressed as specific binding
sites per mg of cytosolic protein (fmol mg–1 protein). The cut-off
value for both oestrogen receptors and progesterone receptors was
10 fmol mg–1 protein as established in our laboratory.
Cathepsin-D assay
Total CD concentrations were measured using a standard assay
(IRMA, ELISA Cath-D kit; CIS Bio International, Gif-sur-Yvette,
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in 1/40 and 1/80 dilutions of the reconstituted cytosols, both in
duplicate.
Statistics
Survival analyses were performed by constructing Kaplan–Meier
DFS, OS and LRR curves (Kaplan and Meier, 1957), where differ-
ences between curves were evaluated by the log-rank test. Cox and
logistic regression analysis were used to estimate the relative risks
for relapse, locoregional recurrent and death (Tormod and Egil,
1985). Selection of prognostic variables with the highest signifi-
cant effect in DFS, LLR and OS was performed in the Cox’s model
using the step-wise regression method in multivariate analysis.
Only variables for which P < 0.05 were retained in the final model.
Relative risks and 95% confidence intervals are presented only for
retained variables, significant in the multivariate analysis. Tumour
size and differentiation grade are continuous variables with
scores 1–3.
RESULTS
The frequency of amplification measured in 152 primary breast
tumours was 26.9% for c-myc and 20.4% for c-erbB-2, whereas
47.4% of tumours produced high concentrations of CD (³ 60 pmol
mg–1 protein). Moreover, overexpression of c-myc was found in
28.3% and of c-erbB-2 in 29.6% of tumours (Table 1). The magni-
tude of c-myc amplification ranged between 3 and 7 gene copies,
whereas c-erbB-2 amplification ranged between 3 and 10 copies.
The overexpression was stronger for c-erbB-2 (3–12 times) than
for c-myc (3–6 times) (data not shown). The median CD concen-
tration was 59 pmol mg–1 protein (range 23.2–132 pmol mg–1
protein). The patients examined were divided in subgroups: (1)
according to survival: early relapse (ER; before 3 years); disease-
free survival (DFS; median 5 years); overall survival (OS; median
5 years) and (2) according to locoregional recurrence (LRR).
Statistic analysis for the ER
By univariate analysis, the variables found to negatively affect ER
were CD, c-myc amplification, lymph node status, tumour size,
differentiation grade, c-myc overexpression and age. ER was
c-myc in breast cancer 1387
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Table 1 Distribution of 152 patients on the basis of factors examined
Factor No. of patients %
Age
≤50 38 25.0
50–56 58 38.2
>60 56 36.8
Menopausal status
Pre/peri 43 28.3
Post 109 71.7
Tumour size
T1 44 29.0
T2 81 53.3
T3 27 27.7
Lymph node status
Positive 88 57.9
Negative 64 42.1
Grade
I 22 14.5
II 97 63.8
III 33 21.7
Oestrogen receptor
Positive 125 82.5
Negative 27 17.8
Progesterone receptor
Positive 130 85.5
Negative 22 14.5
c-erbB-2
Amplification 31 20.4
Overexpression 45 29.6
Cathepsin-D
Positive 72 47.4
Negative 80 52.6
C-myc
Overexpression 43 28.3
Amplification 41 26.9
3 years relapse-free survival 106 69.7
Relapse-free survivala 85 55.9
Overall survivala 104 68.4
Locoregional recurrence 21 13.8
aMedian follow up 5 years
Table 2 Univariate and multivariate analysisa for early recurrence of 152
primary breast cancer patients
95%
Factor Univariate Multivariate Relative confidence
P-value P-value risk intervals
C-myc amplification 0.012 NS – –
c-myc overexpression 0.0088 NS – –
Cathepsin-D <0.0001 0.0001 3.12 2.32–4.19
c-erbB-2 amplification NS NS – –
c-erbB-2 overexpression NS NS – –
Oestrogen receptor 0.018 NS – –
Progesterone receptor NS NS – –
Differentiation grade 0.0084 0.035 – 1.07–3.20
Lymph node status 0.0018 0.0012 2.15 1.32–3.51
Tumour size 0.0027 NS – –
Menopausal status NS NS – –
Age 0.046 NS – –
aCox regression analysis; NS, not significant (P < 0.05); median follow-up
60 months.
Table 3 Univariate and multivariate analysisa for relapse-free survival of
152 primary breast cancer patients
95%
Factor Univariate Multivariate Relative confidence
P-value P-value risk intervals
c-myc amplification 0.0016 NS – –
c-myc overexpression <0.0001 0.0001 2.25 1.55–3.05
Cathepsin-D 0.0022 NS – –
c-erbB-2 amplification NS NS – –
c-erbB-2 overexpression 0.031 0.0302 1.88 1.15–3.07
Oestrogen recepter 0.019 0.0030 0.25 0.11–0.63
Progesterone recepter 0.028 NS – –
Differentiation grade 0.0074 NS – –
Lymph node status 0.0055 0.0047 2.54 1.65–3.91
Tumour size 0.0010 NS – –
Menopausal status NS NS – –
Age NS NS – –
aCox regression analysis; NS, not significant (P < 0.05); median follow-up 60
months.positively affected by oestrogen receptor but was unaffected by
menopausal status, progesterone receptor, or amplification and
overexpression of c-erbB-2. Multivariate analysis again reveals
CD (P = 0.0001) as the most important variable influencing ER
and the precision of the prediction is statistically improved when
lymph node status and grade (P = 0.012 and P = 0.035 respec-
tively) are considered (Table 2). In a previous study we showed
that the concentration of CD was found to be positively correlated
with c-myc amplification and overexpression (Scorilas et al,
1993). This finding, by multivariate analysis, reduces the signifi-
cance of c-myc oncogene, due to technically easier determination
of CD.
Univariate and multivariate analysis for DFS
Relapse free survival as shown in Table 3 was negatively affected
by c-myc overexpression and amplification, tumour size, CD
concentration, lymph node status, differentiation grade and
c-erbB-2 overexpression; however, it was positively affected by
the oestrogen and progesterone receptors, and remained unaffected
by age and c-erbB-2 amplification. By multivariate analysis,
c-myc overexpression and lymph node status emerged as the
variables with the strongest influence on DFS. Prediction,
however, is improved statistically when oestrogen receptor and C-
erbB-2 overexpression are considered. In our previous study
(Scorilas et al, 1993) we reported positive correlation between c-
myc overexpression and amplification. This reduces the signifi-
cance of c-myc amplification as shown by multivariate analysis.
The Kaplan–Meier curves (Figures 1A and 2A) also show that
patients with c-myc overexpression or amplification have a
smaller probability for longer DFS than patients without either of
them. The difference in DFS effect was greater for c-myc over-
expression than for c-myc amplification.
Statistic analysis for OS
Overall survival is negatively influenced by the following vari-
ables: c-myc amplification and overexpression, tumour size,
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Figure 1 Kaplan–Meier survival plots of DFS (A), OS (B) and LRR (C) of
152 patients with c-myc normal and c-myc amplified. Differences among the
two groups for DFS, OS and LRR were determined by log-rank test.
Numbers in parentheses indicate the number of failures/total number of
patients in each group
Figure 2 Kaplan–Meier survival plots of DFS (A), OS (B) and LRR (C) of
152 patients with c-myc normal and c-myc overexpressed. Differences
among the two groups for DFS, OS and LRR were determined by log-rank
test. Numbers in parentheses indicate the number of failures/total number of
patients in each groupc-erbB-2 overexpression, lymph node status and differentiation
grade (Table 4). Again, the role of oestrogen and progesterone
receptors is protective, whereas age, menopausal status, CD and
c-erbB-2 amplification do not seem to influence OS. The
Kaplan–Meier survival curves (Figures 1B and 2B) show the
reduced probability of patients with c-myc amplification or c-myc
overexpression for OS in contrast to those without the two
markers. Using multivariate analysis we proved that OS can be
predicted by combining the variables: c-myc amplification, lymph
node involvement and oestrogen receptor. The prediction is
improved if progesterone receptor, tumour size and c-erbB-2
overexpression are taken into account as well.
Analysis for LRR
We observed that 27% and 28% of patients with c-myc amplifica-
tion and overexpression respectively developed locoregional
recurrence, while only 9% and 8% of patients without c-myc
amplification and overexpression respectively had locoregional
recurrence (Figures 1C and 2C). In Cox univariate analysis, c-myc
amplification, c-myc overexpression, CD concentration, c-erbB-2
amplification and tumour size have a positive effect on loco-
regional recurrence, while oestrogen and progesterone receptors
have a negative effect (Table 5). The Kaplan–Meier curves
(Figures 1C and 2C) also show that patients with c-myc amplifica-
tion or overexpression have a greater chance of developing LRR
than patients without them. Multivariate analysis suggests that
high CD concentration is the most important variable for LRR.
The positive correlation between CD concentration and c-myc
amplification and overexpression, reported previously by our
group (Scorilas et al, 1993), reduces in multivariate analysis the
role for c-myc determination for prediction of disease course.
DISCUSSION
Breast cancer is the most common form of malignancy among
women today. It would be beneficial for patients to have tools
available that could more reliably predict the rate of recurrence in
primary breast cancer, in addition to the classical prognostic
factors. In recent years, many biological markers have been
studied for their correlation with prognosis (McGuire et al, 1991;
Gasparini et al, 1992; Osborne et al, 1992; Foekens et al, 1996;
Nass and Dickinson, 1996; Thor and Yaudell, 1996). The myc
family of nuclear proto-oncogenes plays critical roles during cell
growth, differentiation and transformation. Although the molec-
ular mechanisms underlining myc-mediated cellular transforma-
tion are still under investigation, evidence is accumulating that
c-myc transcriptionally controls the expression of a diverse group
of genes, and that its deregulation leads to a cellular imbalance in
the expression of genes that control both proliferation and death.
Amplification of the c-myc locus in breast cancer tissue has
been observed in many studies (Berns et al, 1992a, 1992b; Borg et
al, 1992; Watson et al, 1993; Lonn et al, 1995). The reported
frequency of amplification varies greatly (from 4% to 52%) in
these studies, but the overall mean appears to be about 20%. There
is also considerable variability in the predictive value of c-myc
amplification and correlation with other prognostic markers of
breast cancer. Some reports indicate that c-myc amplification is
predictive for shortened relapse-free and/or overall survival (Berns
et al, 1992a; Borg et al, 1992; Lonn et al, 1995), while Berns et al
(1995) upon concurrent examination of c-erbB-2, c-myc and int-2
showed that c-myc was the only oncogene whose amplification
was significantly related with the rate of relapse.
In addition, a number of studies have examined c-myc expres-
sion in breast cancer at both the mRNA and protein levels.
Northern analysis indicated that c-myc mRNA expression was
elevated compared to that observed in normal breast tissue in 70%
(Escot et al, 1986) or 45% (Garcia et al, 1989) of breast tumours.
Immunohistochemistry also has been frequently used to
examine the relative levels of myc protein in mammary tumour
specimens (Pavelic et al, 1992; Pietilainen et al, 1995). Tulchin
et al (1996), using immunohistochemistry, have shown continuity
of c-myc expression during tumour progression, whereas Bland et
al (1995), while studying the co-expression of c-myc with other
oncogenes, report that co-expression of c-myc, Ha-ras and c-fos
function as a strong prognostic correlate for recurrence and
survival. Variation in results throughout the literature is not
surprising given the broad range of sample size, composition
and follow-up, as well as inconsistencies in experimental and
statistical methodology.
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Table 4 Cox univariate and multivariate analysisa for the overall survival of
152 primary breast cancer patients
95%
Factor Univariate Multivariate Relative confidence
P-value P-value risk intervals
c-myc amplification <0.0001 0.0006 3.10 2.18–4.41
c-myc overexpression 0.0095 NS – –
Cathepsin-D NS NS – –
c-erbB-2 amplification NS NS – –
c-erbB-2 overexpression 0.0021 0.024 1.62 1.01–2.59
Oestrogen receptor 0.0006 0.0053 0.48 0.32–0.71
Progesterone receptor 0.0041 0.025 0.52 0.29–0.94
Differentiation grade 0.042 NS – –
Lymph node status 0.0081 0.0043 3.30 2.18–4.98
Tumour size 0.0021 0.015 1.84 1.15–2.94
Menopausal status NS NS – –
Age NS NS – –
aCox regression analysis; NS, not significant (P < 0.05); median follow-up
60 months.
Table 5 Univariate and multivariate analysisa for locoregional recurrence of
152 primary breast cancer patients
95%
Factor Univariate Multivariate Relative confidence
P-value P-value risk intervals
c-myc amplification 0.0024 NS – –
c-myc overexpression 0.0075 NS – –
Cathepsin-D 0.0016 0.0067 4.2 2.52–6.99
c-erbB-2 amplification 0.0022 0.0091 2.7 1.50–4.86
c-erbB-2 overexpression NS NS – –
EsR 0.0063 0.019 0.32 0.20–0.52
PgR 0.012 NS – –
Differentiation grade NS NS – –
Lymph node status NS NS – –
Tumour size 0.018 NS – –
Menopausal status NS NS – –
Age NS NS – –
aCox regression analysis; NS, not significant (P < 0.05); median follow-up
60 months.In the present study, the distribution of c-myc amplification and
overexpression, c-erbB-2 amplification and overexpression and
high CD concentration (Table 1) are in agreement with data
reported in the literature. With respect to the prognostic value of
c-erbB-2 for DFS and OS, we observed a discriminative power
only for its overexpression, which was reduced in multivariate
analysis (Tables 3 and 4). More important is our finding
concerning the clinical impact of c-myc amplification and over-
expression. This study (Tables 3 and 4) suggests that both are
highly significant for DFS and OS of patients, albeit in multi-
variate analysis only c-myc overexpression for DFS and c-myc
amplification for OS remain statistically significant. For ER the
best predictors of the new markers examined are high CD concen-
tration, c-myc amplification and c-myc overexpression (Table 2),
but following multivariate analysis, only the CD remains relevant,
which suggests that the prognostic power of the three variables is
not additive. In general, the prognostic relevance of c-myc ampli-
fication and overexpression overlap as we reported (Scorilas et al,
1993) and the determination of one of them only is sufficient. The
association of LRR with high CD concentration, c-erbB-2 amplifi-
cation and c-myc amplification and overexpression is also impor-
tant. Nevertheless, their impact is not additive and following
multivariate analysis only high CD concentration remains statisti-
cally significant and can be exploited as a marker for modification
of patient treatment (Table 5). The present study also reveals that
for ER and LRR, c-erbB-2 amplification and overexpression have
smaller prognostic value from the c-myc amplification and over-
expression, although for the former these values are additive
(Table 2 and 5). For ER the only new variable which has signifi-
cance in multivariate analysis is high CD (Table 2). The observa-
tion, which to the best of our knowledge has not been reported
previously, is the positive association between c-myc and LRR.
Therefore, we can propose that patients showing c-myc amplifica-
tion or overexpression have a tendency for locoregional recur-
rence, which could be exploited as a marker for modification of
patients’ treatment.
In conclusion, c-myc amplification can be used as a prognosti-
cator for overall survival, whereas c-myc overexpression for
relapse-free survival of breast cancer patients. The best of the new
predictors for early relapse remains high CD concentration, while
c-myc amplification and overexpression manifest a tendency for
locoregional recurrence.
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